Novartis Q4 Results
↑
Content
Click below to navigate
through the document
Expect to continue our innovation momentum in 2024...
↓
Company overview
Financial review
Conclusions
Appendix
2024 selected key events (expected)
Regulatory
decisions
Submissions
FabhaltaⓇ PNH
References
H1 2024
H2 2024
EU, JP
US, EU
Kisqali® HR+/HER2- adj.BC
Atrasentan IgAN
US
Iptacopan C3G
US
EU
Iptacopan IgAN
US
PluvictoⓇ mCRPC, pre-taxane
US
Remibrutinib CSU
US, EU, JP
ScemblixⓇ CML 1L
LutatheraⓇ GEP-NET 1L G2/G3
US
EU
JP
Readouts
ScemblixⓇ CML 1L
Ph3 (ASC4FIRST)
Ph3 starts
ZolgensmaⓇ SMA IT
XXB750 Hypertension
PluvictoⓇ Oligometastatic prostate cancer
Opnurasib 1L NSCLC (combo)1
Ph3
Ph2/3
Ph3 (STEER)
Ph2
INNOVATION
-
C3G complement 3 Glomerulopathy.
IgAN-immunoglobulin A nephropathy.
FIR - first interpretable results.
NSCLC Non-small cell lung cancer.
-
1. This is a seamless Ph2/3 trial.
-
PNH paroxysmal nocturnal hemoglobinuria.
mCRPC – metastatic castration-resistant prostate cancer.
CCSU - Chronic spontaneous urticaria. CML - Chronic myeloid leukemia. SMA Spinal muscular atrophy.
□ NOVARTIS | Reimagining Medicine.
Novartis Q4 Results | January 31, 2024
19View entire presentation